Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

T. van Meerten; R.S. van Rijn; A. Hagenbeek; S.B. Ebeling

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

Translated title of the contribution: Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

T. van Meerten
, R.S. van Rijn
, A. Hagenbeek
, S.B. Ebeling

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
Original language	Undefined/Unknown
Pages (from-to)	4027-4035
Number of pages	9
Journal	Clinical Cancer Research
Volume	12
Issue number	13
Publication status	Published - 2006

Cite this

@article{541a0c29e99648e8b87fd304c5b2110d,

title = "Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.",

author = "\{van Meerten\}, T. and \{van Rijn\}, R.S. and A. Hagenbeek and S.B. Ebeling",

year = "2006",

language = "Undefined/Unknown",

volume = "12",

pages = "4027--4035",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

AU - van Meerten, T.

AU - van Rijn, R.S.

AU - Hagenbeek, A.

AU - Ebeling, S.B.

PY - 2006

Y1 - 2006

M3 - Article

SN - 1078-0432

VL - 12

SP - 4027

EP - 4035

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -